# CardioSeq: Impact of WGS in Individuals With CVD

> **NCT05656183** · NA · UNKNOWN · sponsor: **Illumina, Inc.** · enrollment: 1500 (estimated)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DIAGNOSTIC_TEST:** TruGenome Cardiovascular Disease test

## Key facts

- **NCT ID:** NCT05656183
- **Lead sponsor:** Illumina, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-06
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2024-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656183, "CardioSeq: Impact of WGS in Individuals With CVD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05656183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*